| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
risperidone had favourable cost-benefit ratios relative to conventional antipsychotic treatment in a study that investigated a scenario in which all patients hospitalised with newly diagnosed schizophrenia received conventional antipsychotic therapy for 6 months, and then those who did not respond received a 6-month trial of risperidone or clozapine. |
1998-09-22 |
2023-08-12 |
Not clear |
| R I Hecto. The use of clozapine in the treatment of aggressive schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 5. 1998-09-02. PMID:9653529. |
the use of clozapine in the treatment of aggressive schizophrenia. |
1998-09-02 |
2023-08-12 |
Not clear |
| R I Hecto. The use of clozapine in the treatment of aggressive schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 5. 1998-09-02. PMID:9653529. |
there is now a broad consensus about the benefits of clozapine which supports the use of clozapine as a first-line treatment of schizophrenia. |
1998-09-02 |
2023-08-12 |
Not clear |
| R I Hecto. The use of clozapine in the treatment of aggressive schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 5. 1998-09-02. PMID:9653529. |
this review also describes the results of clozapine on aggressive and violent assault in a patient population characterized by severe functional deficits, typically chronic schizophrenia with severe impairment, chronic brain syndromes, and developmental handicap. |
1998-09-02 |
2023-08-12 |
Not clear |
| J Lauriello, D H Mathalon, M Rosenbloom, E V Sullivan, W O Faustman, D L Ringo, K O Lim, A Pfefferbau. Association between regional brain volumes and clozapine response in schizophrenia. Biological psychiatry. vol 43. issue 12. 1998-08-26. PMID:9627742. |
association between regional brain volumes and clozapine response in schizophrenia. |
1998-08-26 |
2023-08-12 |
Not clear |
| J Lauriello, D H Mathalon, M Rosenbloom, E V Sullivan, W O Faustman, D L Ringo, K O Lim, A Pfefferbau. Association between regional brain volumes and clozapine response in schizophrenia. Biological psychiatry. vol 43. issue 12. 1998-08-26. PMID:9627742. |
clozapine has shown considerable therapeutic promise in the treatment of schizophrenia; however, the clinical risks and initial high treatment costs associated with its administration motivate the search to identify patients who will best respond. |
1998-08-26 |
2023-08-12 |
Not clear |
| M Masellis, V Basile, H Y Meltzer, J A Lieberman, S Sevy, F M Macciardi, P Cola, A Howard, F Badri, M M Nöthen, W Kalow, J L Kenned. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 19. issue 2. 1998-08-21. PMID:9629566. |
serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. |
1998-08-21 |
2023-08-12 |
Not clear |
| R Rosenheck, J Tekell, J Peters, J Cramer, A Fontana, W Xu, J Thomas, W Henderson, D Charne. Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Archives of general psychiatry. vol 55. issue 7. 1998-07-23. PMID:9672052. |
department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1998-07-23 |
2023-08-12 |
Not clear |
| D L Copolov, W R Bell, W J Benson, N A Keks, D C Strazzeri, G F Johnso. Clozapine treatment in Australia: a review of haematological monitoring. The Medical journal of Australia. vol 168. issue 10. 1998-07-09. PMID:9631674. |
clozapine is an atypical antipsychotic drug indicated for patients with schizophrenia in whom traditional antipsychotic drugs (such as haloperidol or the phenothiazines) are ineffective, or in those who experience intolerable adverse effects. |
1998-07-09 |
2023-08-12 |
Not clear |
| Y Jin, S G Potkin, C A Sandman, W E Bunne. Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment. Clinical EEG (electroencephalography). vol 29. issue 2. 1998-07-02. PMID:9571294. |
topographic analysis of eeg photic driving in patients with schizophrenia following clozapine treatment. |
1998-07-02 |
2023-08-12 |
Not clear |
| N Nacasch, O T Dolberg, S Hirschmann, P Dannon, L J Grunhau. Clozapine for the treatment of agitated-depressed patients with cognitive impairment: a report of three cases. Clinical neuropharmacology. vol 21. issue 2. 1998-06-23. PMID:9579302. |
clozapine, an atypical antipsychotic, is mainly approved for the treatment of resistant schizophrenia. |
1998-06-23 |
2023-08-12 |
Not clear |
| R W Buchanan, A Breier, B Kirkpatrick, P Ball, W T Carpente. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. The American journal of psychiatry. vol 155. issue 6. 1998-06-18. PMID:9619146. |
in a preliminary report, the authors observed that clozapine was superior to haloperidol in the treatment of positive and negative symptoms in stable outpatients with schizophrenia. |
1998-06-18 |
2023-08-12 |
Not clear |
| H Jones, V A Curtis, P Wright, J V Luce. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. The American journal of psychiatry. vol 155. issue 6. 1998-06-18. PMID:9619161. |
the authors examined the effect of prolonged clozapine treatment on central serotonergic (5-ht) function in schizophrenia. |
1998-06-18 |
2023-08-12 |
Not clear |
| L Lahdelma, A Ahokas, L C Andersson, M Huttunen, S Sarna, S Koskimie. Association between HLA-A1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication. Tissue antigens. vol 51. issue 2. 1998-06-01. PMID:9510376. |
association between hla-a1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication. |
1998-06-01 |
2023-08-12 |
Not clear |
| J I Tracy, C A Monaco, G Abraham, R C Josiassen, B G Polloc. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. The Journal of clinical psychiatry. vol 59. issue 4. 1998-05-29. PMID:9590669. |
relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. |
1998-05-29 |
2023-08-12 |
Not clear |
| J I Tracy, C A Monaco, G Abraham, R C Josiassen, B G Polloc. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. The Journal of clinical psychiatry. vol 59. issue 4. 1998-05-29. PMID:9590669. |
this study examines anticholinergic burden in schizophrenia patients taking clozapine and risperidone and tests whether this burden is associated with cognitive deficits. |
1998-05-29 |
2023-08-12 |
Not clear |
| W H Reid, M Maso. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. The Journal of clinical psychiatry. vol 59. issue 4. 1998-05-29. PMID:9590670. |
we wished to study long-term psychiatric hospital utilization in a large sample of patients with schizophrenia and/or schizoaffective disorders who were treated with clozapine for up to 4.5 years, and to determine whether or not the reduction in hospital utilization we previously observed in smaller groups for up to 2.5 years was sustained with larger groups and in the longer term. |
1998-05-29 |
2023-08-12 |
Not clear |
| G Ginsberg, S Shani, B Le. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. PharmacoEconomics. vol 13. issue 2. 1998-05-28. PMID:10178649. |
cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in israel. |
1998-05-28 |
2023-08-12 |
Not clear |
| G Ginsberg, S Shani, B Le. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. PharmacoEconomics. vol 13. issue 2. 1998-05-28. PMID:10178649. |
in this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. |
1998-05-28 |
2023-08-12 |
Not clear |
| G Ginsberg, S Shani, B Le. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. PharmacoEconomics. vol 13. issue 2. 1998-05-28. PMID:10178649. |
the lifetime drug-treatment cost incurred by a patient with schizophrenia in israel was $us7561 (1996 values) with an initial 6-month trial with risperidone, compared with $us6326 with clozapine and $us3360 with typical antipsychotics. |
1998-05-28 |
2023-08-12 |
Not clear |